ALSO NOTED: Europe expands Synvisc approval; FDA issues "approvable" letter for paliperidone; and much more...

> European regulators have agreed to expand the approval of Genzyme's Synvisc to include osteoarthritis of the ankle and shoulder. Report

> J&J says its subsidiary has received an approvable letter from the FDA for paliperidone as a therapy for schizophrenia. But the drug maker did not say what issues were still left to be resolved. Report

> Antisoma says its aptamer therapy AS1411 produced positive Phase I data in a cancer trial. Report

> Acambis has sold Berna Products--which distributes an oral typhoid vaccine in North America--to Crucell for $16.5 million. Report

> Accentia Biopharmaceuticals has gained $25 million in debenture financing. Report

> A combinational therapy of Herceptin and hormonal treatments extended progression-free survival of a certain group of women with advanced breast cancer. Report

> Roche announced that Phase II data supported the combination of Xeloda with Herceptin and Taxotere for breast cancer. Report

> Novartis says that new four-year data for Femara indicates a reduced rate of risk for a recurrence of breast cancer compared with the standard therapy Tamoxifen. Report

> The FDA has expanded the approved use of Rituxan. Report

And Finally… Two American scientists, Andrew Z. Fire and Craig C. Mello, won the Nobel prize for medicine for their work in RNA interference. Article